Health Business Blog

Health care business consultant and policy expert David E. Williams share his views

Healthcare predictions for 2022

man g5b5bbecab 1280
Looking ahead

Pandemics, wars and other large-scale dislocations lead to fundamental changes in the ensuing years and decades. Two years into COVID-19, I’m ready to hazard a few guesses about what lies ahead for healthcare. These 7 changes should start becoming visible in 2022. Some are more COVID-related than others.

Please share your feedback: dwilliams@healthbusinessgroup.com.

  1. Retailers make care more consumer friendly
  2. COVID becomes less political
  3. Cybersecurity threats in healthcare get bigger and scarier
  4. Consumers stake a claim to their own health data
  5. Climate change becomes a major healthcare issue
  6. Clinical trials simultaneously decentralize and centralize
  7. Old age is pushed back

1. Retailers make care more consumer friendly

Hospital-based health systems are trying to be consumer-centric, but few are succeeding. Some with the best-trained and most capable clinicians talk a good game but are hellish to deal with as a consumer: gaining initial access, scheduling, waiting, follow-up, electronic communications, billing, etc. Here I’m writing from personal experience in Boston, including a recent consumer nightmare that was resolved only when the CEOs of my health plan and hospital agreed to intervene.

Retailers are stepping into healthcare and definitely have a more consumer friendly mindset. The real questions are whether they can address the challenges that make healthcare delivery harder than other consumer services and can overcome the conflicts inherent in third-party reimbursement. I’m most bullish on Walgreens with its recent VillageMD and CareCentrix investments, which take the company directly into primary care and care at home. Walmart — despite its healthcare executive turnover and lack of clear top-level commitment to healthcare—comes second because of its laser focus on reducing costs. It’s in their DNA and matters hugely to consumers.

Amazon has massive potential, of course but I’ve yet to be persuaded that their hard-charging approach will play out in care delivery, especially without a physical footprint. And I’ve never bought into the logic of the CVS/Aetna combination nor been impressed with CVS’s IT infrastructure.

If retailers succeed, there’s a chance they –and other enlightened and well-capitalized primary care providers– will take over the primacy now enjoyed by hospital-based Integrated Delivery Networks (IDNs). This could happen rather fast, thanks to Medicare’s Direct Contracting program, which offers primary care providers major influence on referrals and spending, plus access to patient data. If big primary care providers like Walgreens’ Village MD learn how to manage this opportunity well, Medicare Advantage and commercial risk will follow quickly.

Alternative payment model experts such as Archway Health are showing risk-bearing physician groups (not just retailers) how to gain up to 20x in Medicare revenue overnight under Direct Contracting, and how to actively manage specialist and hospital referrals without being dictated to by IDNs.

2. COVID becomes less political

The response to COVID in the US –and parts of Europe and Latin America—has been blunted by political divisions. COVID denial, vaccine ‘hesitancy,’ and anti-mask sentiment are the kinds of barriers I’m talking about.  But divisions are already receding.

What’s behind the rosy outlook? Vaccines work well enough that the vaccinated are not so badly threatened by the unvaccinated. And new COVID treatments mean even almost everyone can be kept out of the hospital, assuming real world experience matches clinical trial results.

Paradoxically, vaccine mandates will make COVID less political over time, even if they inflame tensions in the near term. As my father, retired Chief Scientist for the Insurance Institute of Highway Safety recounts, when seat belts were first available, less then 10 percent of people used them. State laws drove usage toward 90 percent, despite the contention that belt use was a matter of personal freedom and misguided beliefs that belts could harm people by trapping them in their cars or causing injuries during a crash.

Seat belts are not political now. Once people started buckling up, they reconciled their views to their actions. The same can happen with vaccines.

This prediction could be completely wrong. Right now, the Omicron variant is turning countries against one another, Merck’s pill is showing weaker results than expected, and there are political leaders actively promoting division and the politicization of everything. But I’m sticking with a more optimistic view.

3. Cybersecurity threats in healthcare get bigger and scarier

Ransomware made the news in 2021 as hospitals were hit by an unprecedented wave of attacks. It was expensive for hospitals and insurance companies, and a hassle for employees. But few patients were directly affected. That has the potential to change dramatically.

The whole information economy –but especially healthcare—is built on a flawed foundation. Microsoft Windows, which powers computers, networks and many medical devices is intrinsically insecure. Devices from MRIs to ventilators are stuffed with hackable microcontrollers that are rarely secured properly.

Cyber dangers are built right into the business models of certain equipment vendors, whose service and warranty agreements forbid customers or third parties from auditing or updating their equipment. These agreements effectively lock in vulnerabilities, such as when vendors apply custom patches to outdated Windows XP based systems and neglect to penetration test them regularly.

The danger is not limited to hospitals and medical devices. Pharmaceutical development and manufacturing are vulnerable to threats ranging from spyware, to ransomware, to malware that ruins batches and even shuts down or destroys production equipment.

Things may get worse before they stabilize or improve. For example, new Internet of Things (IoT) sensor networks will multiply the attack surface if deployed on insecure infrastructure.

Unlike financial services and defense, healthcare as a whole lacks the sophistication, resolve and funding to stop cyberattacks. Large-scale cyberattacks in healthcare are not inevitable, but the industry is among the economy’s most vulnerable and becoming more so.

4. Consumers stake a claim to their own health data

Data tokenization by Datavant and HealthVerity enables mixing and matching of disparate sources at the patient level and the generation of valuable clinical and commercial insights. We are witnessing rapid growth of the real-world data ecosystem and tremendous value creation.

But individual patients –whose data are being leveraged to build these fortunes—are not really in the conversation and are certainly not benefiting financially. At a recent health data conference, I heard CEOs confidently assure the audience that patients were grateful to be able to contribute their data for the betterment of others.

That sounded pretty self-serving to me, and I heard a few whispers to the same effect.

In 2022 I expect patients to start waking up and asserting themselves, even if the impact is limited initially. We won’t see many companies paying patients for their data, but there will be more of an effort to let individuals control how their data are used and to receive something of value in return. A few companies such as Ciitizen (recently acquired by Invitae), Picnic Health, and Seqster give patients control of their medical and health data and some chance to benefit from it in their care journeys. RxRevu’s founder is launching a new venture (I’m on the advisory board) to take the concept even further.

If you’re skeptical that consumers will wake up, look to Europe where GDPR –the European General Data Protection Regulation– has made consumers much more aware of the information being collected about them and how it’s used. GDPR also includes provisions for individuals to request their own information and to have it deleted. Similar concepts are progressing in the US, starting with the California Consumer Privacy Act.

Healthcare data is a little different, but not completely distinct. The 21st Century Cures Act enables patients to get easy access to their medical data and share it with others. Its full implementation will put patients in the driver’s seat. Now patients just need to learn how to drive and figure out where to go.

5. Climate change becomes a major healthcare issue

I’ve worried about climate change for a long time, though until about five years ago I thought it would affect my grandkids, not me. Weird and wild weather induced by climate change is here now, though, causing disruptions to the rich as well as the poor. Hurricanes, fires, floods and the rapid emergence of new pathogens are already wreaking havoc beyond expectations. It’s going to get a lot worse -even if it’s not always apparent year to year.

Emerging health problems include heat-related illnesses, water-borne and vector-borne diseases, and injuries from extreme weather. Psychiatrists are also seeing patients with a new complaint: climate anxiety. Good luck curing that one!

Near-term imperatives are to build more resilient healthcare infrastructure (like hospitals with backup generators on the roof), restore and improve global health surveillance, and direct research and development dollars to prevent and cure new diseases. Some expect pandemic-induced public health spending to decay once the immediate crisis recedes. I don’t think so. Instead, there will be sustained public and private investment because we’re not going back to the old normal.

6. Clinical trials simultaneously decentralize and centralize

The weird thing about “decentralized” clinical trials (DCTs) is that they actually involve more centralization than traditional trials. DCTs –sometimes called “virtual” trials—have been discussed for years but radically accelerated during the pandemic. DCT enablers including Medable, Science 37 and Curavit have captured investor imagination and raised hundreds of millions.

The notion is that patients in clinical trials for new drugs and devices should not have to travel to a physical site –usually a hospital or clinic—to be examined, observed and measured. Remote monitoring, video calls, and electronic surveys should suffice. It’s not easy to run trials this way, but initial results are promising. Trials enroll patients faster and data integrity is high.

It’s the patients in these trials that are decentralized. Instead of going into one of a few or several sites, each patient becomes a site. But the trial sponsor has the opportunity to centralize functions –such as recruiting, drug supply, and payments– rather than spreading resources to multiple physical sites. That’s a positive for everyone –except the traditional sites that lose out on the work.

Sponsors are committed to increasing diversity in trials so participants more closely match the racial, ethnic, language, age, gender and geographic profiles of those affected by the condition being addressed. DCTs are a promising way to achieve diversity. Science 37 is emphasizing this advantage; Diversity & Inclusion is one of its five main offerings.

Expect to see more DCTs, especially as sponsors compete for the attention of the limited number of patients who are candidates for trials. Patients with certain (i.e., lucrative-to-pharma) diseases often have a choice of trials and enroll based on convenience. Not surprisingly, consumer-oriented providers are turning their attention to trials. CVS Health is introducing clinical trials services and 2020 On-site shifted its mobile vision clinics from exams for employers to exams for clinical trial sponsors.

To really increase recruitment, we could allow sponsors to pay subjects to participate in trials and stop worrying so much about offering “unfair inducements.” I’m not predicting that change for 2022, however.

7. Old age is pushed back

We still label people as “seniors” when they turn 65, just like we did 50 years ago when life expectancy was almost 10 years lower. Today’s typical 75-year-old is more like the 65-year-old of yore in terms of health and productive years ahead. But COVID strikes older people hard, and those as young as 50(!) were put in the “old” column for pandemic safety purposes. Therefore, if I’d made this prediction in early 2020 I would have been dead wrong. But with higher vaccination rates and better treatments, older people will breathe easier, get back to work and stay there.

Why? They are needed in the workforce to address shortages caused by the Great Resignation and reduced immigration –especially in healthcare– and with the shift from defined benefits to 401(k) accounts they don’t have enough saved for retirement.

Another thing I’ve noticed is that young adults don’t shun seniors the way my generation did, so the workplace should become less hostile for the aging.

That’s a happy note to end on.

CNS drug development roundtable with Annovis and Clene

Alzheimer’s, Parkinson’s, ALS, MS –these are all serious or fatal neurodegenerative diseases that lack effective treatments. Thankfully, innovative companies are developing promising, novel therapies in the field.

Maria Maccecchini is founder and CEO of Annovis Bio, which is focused on improving axonal transport. Robert Glanzman is Chief Medical Officer of Clene, whose approach relies on nanotherpauetics. Our discussion centers on the particular challenges in developing CNS drugs, how Maria and Robert have steered their companies throughout the last two challenging years, and what they hoped to achieve during the JP Morgan Healthcare Conference.

The companies’ approaches –one drug increases energy and the other speed– could be synergistic. If that ends up being the case, remember it all started here on the HealthBiz podcast.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services.


By healthcare business consultant David E. Williams, president of Health Business Group.

Regenerative medicine roundtable with Axogen and Athersys

 

Athersys CEO BJ Lehmann , Axogen EVP and CFO Peter Mariani, and I gathered for a regenerative medicine roundtable discussion in advance of the 2022 JP Morgan Healthcare Conference.

We discussed:

  • A “year of firsts and records” for the regenerative medicine sector
  • Challenges in developing stem cells and other regenerative medicine approaches today, and how they are being addressed
  • Advantages of allogeneic therapies
  • What the next decade will bring

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with Qualio CEO Robert Fenton

Robert Headshot
Qualio CEO Robert Fenton

Robert Fenton was born in Ireland, where he studied pharmacy but then quickly figured out the pharmacist life was not for him. In a stint at big pharma he did come to realize the importance of quality and how it’s not so easy to live up to what you’ve promised, even as a large company with ample resources.

When Robert founded Qualio a decade ago, he already had a remote work approach –which he now prefers to describe as “local everywhere.” Obviously the world has come to his side over the past couple years. 

The company’s quality management system (or eQMS) offering is based on the 12 pillars of quality. It’s built for pharma, med device, software as a med device and even cannabis companies.

Unlike some of the legacy players, Qualio is used throughout the full life sciences ecosystem including by labs, CROs and packaging companies. And although many of the customers listed on Qualio’s website are on the smaller side, Robert boasts that many of the highest profile IPOs are clients and that some of the big boys who are household names use Qualio, too.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services.


By healthcare business consultant David E. Williams, president of Health Business Group.

Elucid CEO Blake Richards on CTA-based arterial analysis software

Blake Richards grew up in Manhattan and thought he would follow his father’s footsteps into finance. But when a job interviewer tried to pin him down on why he wanted to be in that field, he realized it wasn’t really for him. Instead he pursued technology, and more specifically in healthcare.

After spending time at Epic and Deloitte he became CEO of Elucid, a noninvasive cardiac imaging company that competes against HeartFlow, but goes beyond by quantifying plaque based on histopathology. It’s an FDA-cleared tool that helps avoid invasive cath lab procedures and helps physician identify patients who need more aggressive treatments.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services.


By healthcare business consultant David E. Williams, president of Health Business Group.

Essen and Verustat partner on remote patient monitoring. Podcast with Sumir Sahgal, MD

 

Dr. Sahgal
Sr. Sumir Sahgal

Dr. Sumir Sahgal started Essen Health in the Bronx more than 20 years ago to help underserved patients get the care they need to prevent and treat illness. The patient-centered approach has helped Essen grow to almost 30 multi-specialty offices in the Bronx, Brooklyn, Queens and Long Island.

Essen has pioneered innovative approaches and leveraged technology to meet patient needs. In this edition of the HealthBiz podcast Dr. Sahgal describes Essen’s partnership with Verustat, a remote patient monitoring company that provides a platform making it easy for patients to monitor blood pressure, blood sugar and other physiological measures and to get medical and technical help when they need it.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services.


By healthcare business consultant David E. Williams, president of Health Business Group.